Metraipolis › archive › dc_c320d82d8944

Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives — Europe PMC PMID:42206171

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42206171
DOI
10.3389/fphar.2026.1789019
License (as archived)
solo-consultazione
Archived
2026-11-02T11:03:26.156Z
SHA-256 of the archived text
e4bef8e3830ba9a0aa5fd59c8ee5c98636e0367a7b43e50f9a2a484bf9d8018d
Stable URL of this page
https://metraipolis.com/documento/dc_c320d82d8944

How to cite

Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives — Europe PMC PMID:42206171 — Europe PMC (en), https://europepmc.org/article/MED/42206171 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c320d82d8944 (Metraipolis archive dc_c320d82d8944, sha256 e4bef8e3830ba9a0aa5fd59c8ee5c98636e0367a7b43e50f9a2a484bf9d8018d)
BibTeX
@misc{dcc320d82d8944,
  title = {Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives — Europe PMC PMID:42206171},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42206171},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c320d82d8944; sha256 e4bef8e3830ba9a0aa5fd59c8ee5c98636e0367a7b43e50f9a2a484bf9d8018d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42206171. Agents can read the archived copy with the MCP tool read_document.